Líffræðifélag Íslands - biologia.is
Líffræðiráðstefnan 2021
Erindi/veggspjald / Talk/poster E78
Höfundar / Authors: Kristrún Ýr Holm(1,2), Selma Dögg Magnúsdóttir (1), Finnur Eiríksson (1,3), Sigríður Klara Böðvarsdóttir (2), Margrét Þorsteinsdóttir (1,2,3)
Starfsvettvangur / Affiliations: 1. Faculty of Pharmaceutical Sciences, University of Iceland, Reykjavík, Iceland, 2. BioMedical Center, University of Iceland, Reykjavik, Iceland, 3. ArcticMass, Reykjavik, Iceland.
Kynnir / Presenter: Kristrún Ýr Holm
Breast cancer (BC) is the most common cancer among women in Western societies and the second leading cause of cancer deaths. The x-ray mammography is the most common screening method for early BC detection. Unfortunately, often in the early stages of the BC development the tumor is not visible on these mammographs and therefore insufficient for early detection. The importance to detect and treat BC early is critical in order to increase chances of survival. It is therefore a need for more sensitive diagnostic tool for BC. The aim of this study is to use targeted proteomics to identify novel early-stage biomarkers in plasma that can be used as an early diagnostic tool for BC. In this study 100 biobank-based plasma samples, thereof 50 from BC cases and 50 controls, from a well-defined Icelandic BC study cohort were analyzed using MRM proteomics PeptiQuantTM 125-protein human plasma assay kit with UPLC-MRM-MS analysis. Prior to analysis the plasma samples were proteolytically cleaved with trypsin and were concentrated by solid-phase extraction. Data analysis was conducted using Skyline Quantitative Analysis software and SIMCA Pro 17. The MRM assay was successfully implemented for quantification of 125 proteins in human plasma. 112 proteins out of the 125 proteins were successfully quantified in all the plasma samples with acceptable precision and accuracy. Preliminary data suggest that few proteins are up- or downregulated in the plasma samples from the cases compared to controls. These preliminary results indicate a difference in protein concentrations between cases and controls. Further